CN111743851A - Whitening and spot-fading composition and application thereof - Google Patents
Whitening and spot-fading composition and application thereof Download PDFInfo
- Publication number
- CN111743851A CN111743851A CN202010656244.0A CN202010656244A CN111743851A CN 111743851 A CN111743851 A CN 111743851A CN 202010656244 A CN202010656244 A CN 202010656244A CN 111743851 A CN111743851 A CN 111743851A
- Authority
- CN
- China
- Prior art keywords
- whitening
- spot
- extract
- lightening
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a whitening and spot-fading composition and application thereof, wherein the whitening and spot-fading composition comprises the following raw materials: egg yolk oil, shea butter, pterostilbene, vitamin E, hydrolyzed ceramide III, orange peel extract, yeast extract, thyme extract, white willow bark extract, mullein extract, lilium maritimum nerve activity whitening factor, scutellaria baicalensis extract, oxyresveratrol, lactobacillus fermentation lysate, tranexamic acid, VC ethyl ether, water-soluble fullerene, 4-butylresorcinol, and ectoin; and the application of the whitening and spot-lightening composition in cosmetics. The whitening and spot-fading cream has good safety and no toxic or side effect, and the whitening and spot-fading cream inhibits the generation of melanin from two ways of inhibiting the activities of saccharification and tyrosinase by composing the whitening active ingredients.
Description
Technical Field
The invention belongs to the technical field of skin care products, and particularly relates to a whitening and spot-lightening composition and application thereof.
Background
The skin color spot is caused by excessive melanin secretion of melanocytes or uneven melanin distribution of skin, so that spots and patches with darker skin color than normal skin color are locally generated.
The generation of color spots is complicated and mainly classified into intrinsic factors and extrinsic factors. Among them, the intrinsic factors are (1) endocrine: the formation of color spots is largely related to endocrine secretion. Endocrine disorders, imbalanced sex hormone secretion in the body, can affect the production of melanin. In traditional Chinese medicine, endocrine dyscrasia is caused by qi and blood stasis, blood circulation is poor, and toxin metabolism is not clean. Endocrine dyscrasia can also cause emotional instability and indirectly cause color spot formation; (2) inheritance: is a dominant inheritance of autosomes, mainly freckles. Plaques genetically formed through the present or several generations. The external factors are mainly (1) ultraviolet rays: ultraviolet radiation causes new color spots to form and also aggravates existing color spots. The irradiation of ultraviolet rays stimulates, the activity in melanocytes is stimulated, more melanin is formed in the basal layer of the skin to resist the damage of the ultraviolet rays to the skin, and the skin is easy to carry out photosynthesis to grow spots. The original spots are deepened; (2) the light effect reaction: some medical foods are prone to absorb ultraviolet rays, causing pigmentation; (3) external environment: the external air quality, temperature and humidity can also influence the formation of skin melanin, and the air quality is poor, the temperature is too high or too low, and the humidity is too high or too low, so that the normal metabolism of the skin can be influenced, and the formation of color spots is indirectly influenced; (4) living habits: irregular work and rest, unbalanced diet and excessive stress, and the bad living habits influence the metabolism of the body, further influence the metabolism of the skin and increase the melanin.
With the development of economy and the improvement of the cognitive level of people, the pursuit of perfect skin is continuously improved. Healthy, tender, fair, bright and full skin is more and more popular among people. Relevant data show that the proportion of people with color spots in Chinese women can reach 98 percent, so that the market of products for removing the color spots and whitening the skin is huge. The existing freckle-removing and whitening product on the market is full of enamel.
CN100389744A discloses a fibroin freckle-removing whitening cream, which utilizes the extremely strong tyrosinase activity inhibiting function of fibroin, can effectively prevent the formation of skin melanin, and has a good freckle-removing whitening effect, but arbutin is added into the product, and because arbutin has high photosensitivity, a large amount of sunscreen agents are often added into the product, so that the product is easy to bear on skin, and the skin aging is accelerated.
CN100486558A discloses a compound whitening and freckle-removing liquid, which is prepared from water-soluble extracts of plants, kojic acid, vitamin A, caffeic acid, levorotatory vitamin C, ferulic acid, vitamin B3, hyaluronic acid, trimethylglycine, water-soluble ceramide and the like concentrated and extracted from angelica dahurica, liquorice, ginseng, mulberry bark, bearberry, pine bark, ligusticum wallichii, radix sileris, mustard flower, aloe, salvia miltiorrhiza, scutellaria baicalensis, angelica sinensis, lucid ganoderma, ginkgo biloba, gardenia, polygonum multiflorum, radix puerariae, schisandra chinensis, gastrodia elata, frankincense, goldthread root and codonopsis pilosula. The compound whitening and freckle-removing liquid disclosed by the invention can effectively remove senile plaques, chloasma, butterfly spots, cyasma, freckles and the like through the mutual synergistic effect of the traditional Chinese medicine active ingredients and the whitening and freckle-removing active ingredients, avoids relapse, and has the effects of repairing and conditioning the skin.
With the improvement of the living standard and aesthetic standard of people, white and clean skin is more and more advocated. People have higher and higher requirements on the efficacy of cosmetics, natural cosmetics returning to nature are gradually developed, the environmental awareness of people is improved, people begin to pay attention to the concepts of nature, safety, health and environmental protection, the existing whitening and freckle removing products have poor safety, most of the products only inhibit the formation of melanin by inhibiting the activity of tyrosinase, the whitening way is single, and the freckle removing and freckle removing effects are poor. Therefore, there is a need to develop a whitening and freckle-removing product which has high safety and can meet the needs of people.
Disclosure of Invention
In order to solve the technical problems, the invention provides a composition for whitening and lightening spots and an application thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
a whitening and spot-lightening composition comprises the following raw materials: egg yolk oil, shea butter, pterostilbene, vitamin E, hydrolyzed ceramide III, orange peel extract, yeast extract, thyme extract, white willow bark extract, mullein extract, lilium maritimum nerve activity whitening factor, scutellaria baicalensis extract, oxyresveratrol, lactobacillus fermentation lysate, tranexamic acid, VC ethyl ether, water-soluble fullerene, 4-butylresorcinol, and ectoin.
Preferably, the whitening and spot-lightening composition comprises the following raw materials in parts by weight: 1-3 parts of egg oil, 4-6 parts of shea butter, 0.1-0.3 part of pterostilbene, 0.8-1.2 parts of vitamin E, 0.5-1.5 parts of hydrolyzed ceramide III, 0.4-0.6 part of orange peel extract, 0.1-0.2 part of yeast extract, 0.05-0.15 part of thyme extract, 0.1-0.3 part of white willow bark extract, 0.8-1.0 part of mullein extract, 0.05-0.15 part of lilium maritimum nerve activity whitening factor, 0.15-0.25 part of scutellaria baicalensis extract, 0.15-0.25 part of oxidized resveratrol lysate, 0.2-0.4 part of lactobacillus fermentation product, 0.7-0.9 part of tranexamic acid, 0.7-0.9 part of VC ethyl ether, 0.05-0.15 part of water-soluble fullerene, 0.7-0.9 part of 4-butyl resorcinol and 0.01-0.03-0.01 g of hydantoin.
In some preferred embodiments, the weight ratio of pterostilbene, orange peel extract, oxyresveratrol and water-soluble fullerene in the whitening and spot-lightening composition is 2: 5: 2: 1.
in some preferred embodiments, the mass ratio of the egg oil, the lilium maritimum nerve activity whitening factor, the scutellaria baicalensis extract and the ectoin in the whitening and spot-lightening composition is 2: 0.1: 0.2: 0.02.
in some preferred embodiments, the whitening and spot-lightening composition comprises the following raw materials in parts by weight: 2 parts of egg yolk oil, 5 parts of shea butter, 0.2 part of pterostilbene, 1 parts of vitamin E, 1 part of hydrolyzed ceramide III, 0.5 part of orange peel extract, 0.15 part of yeast extract, 0.1 part of thyme extract, 0.2 part of white willow bark extract, 0.9 part of mullein extract, 0.1 part of lilium maritime nerve activity whitening factor, 0.2 part of scutellaria baicalensis extract, 0.2 part of oxyresveratrol, 0.3 part of lactobacillus fermentation lysate, 0.8 part of tranexamic acid, 0.8 part of VC ethyl ether, 0.1 part of water-soluble fullerene, 0.8 part of 4-butylresorcinol and 0.02 part of ectoin.
The invention also provides application of the whitening and spot-lightening composition in cosmetics.
The invention also provides a whitening and spot-lightening cosmetic, which comprises the whitening and spot-lightening composition and acceptable auxiliary materials in the cosmetic.
Preferably, the addition amount of the whitening and spot-lightening composition is 10-16% by mass fraction.
Preferably, the whitening and spot-lightening cosmetic comprises cream, sun cream, face cleaning lotion, emulsion, toner, facial mask or essence.
In some embodiments, the whitening spot-lightening cosmetic comprises, by mass fraction: 10-16% of the whitening and spot-lightening composition, 4% of glycerin, 0.3% of xanthan gum, 2% of trehalose, 1.2% of SS, 1.8% of SSE-20, 0.5% of A165, 0.02% of EDTA, 3% of isononyl isononanoate, 5% of 2EHP, 5% of GTCC, 1.8% of cetostearyl alcohol, 0.08% of tremella heteropolysaccharide, 0.05% of WSR205, 0.15% of hyaluronic acid, 5% of 1.3-butanediol, 0.5% of ZEN, 1% of SEPIPLUS400, 0.02% of heparin sodium, 0.02% of polyglutamic acid, 2% of glycerol glucoside, 0.2% of carrageen, 4% of 1.3-butanediol, 0.25% of acetyl tetrapeptide-2, 0.25% of oligopeptide-4, 1% of E-1008, 0.01% of essence and the balance of water.
The invention has the beneficial effects that:
(1) according to the whitening and spot-fading composition, nineteen active components such as egg yolk oil, shea butter, pterostilbene, vitamin E, hydrolyzed ceramide III, orange peel extract, yeast extract, thyme extract, white willow bark extract, mullein extract, lilium maritimum nerve activity whitening factors, scutellaria baicalensis extract, oxyresveratrol, lactobacillus fermentation lysate, tranexamic acid, VC ethyl ether, water-soluble fullerene, 4-butylresorcinol, ectoin and the like are selected, so that the whitening and spot-fading composition is good in safety and free of toxic and side effects, and the whitening active components are formulated to inhibit the activities of saccharifying enzyme and tyrosinase enzyme, so that the generation of melanin is inhibited, and the whitening and spot-fading effects are remarkable.
(2) Experiments show that the composition has a remarkable inhibiting effect on tyrosinase and saccharification, wherein the inhibiting rate of the tyrosinase activity is 86.4-93.3%, and the highest inhibiting rate on advanced glycation end products (AGEs) reaches 96.73%.
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
Before the present embodiments are further described, it is to be understood that the scope of the invention is not limited to the particular embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The sources of the raw materials used in the present invention are not limited, and the raw materials used in the present invention are all those commonly available in the art unless otherwise specified. The sources of some raw materials of the cosmetic are shown in table 1.
TABLE 1
Example 1
The whitening and spot-fading composition comprises the following raw materials in parts by weight: 1 part of egg oil, 4 parts of shea butter, 0.1 part of pterostilbene, 1.2 parts of vitamin E, 0.5 part of hydrolyzed ceramide III, 0.6 part of orange peel extract, 0.1 part of yeast extract, 0.15 part of thyme extract, 0.1 part of white willow bark extract, 0.8 part of mullein extract, 0.05 part of lilium maritime nerve activity whitening factor, 0.25 part of scutellaria baicalensis extract, 0.15 part of oxyresveratrol, 0.2 part of lactobacillus fermentation lysate, 0.9 part of tranexamic acid, 0.7 part of VC ethyl ether, 0.05 part of water-soluble fullerene, 0.9 part of 4-butylresorcinol and 0.01 part of ectoin.
The preparation method comprises the following steps: and mixing the raw materials, and uniformly stirring to obtain the whitening and spot-fading composition.
Example 2
The whitening and spot-fading composition comprises the following raw materials in parts by weight: 3 parts of egg yolk oil, 6 parts of shea butter, 0.3 part of pterostilbene, 0.8 part of vitamin E, 1.5 parts of hydrolyzed ceramide III, 0.4 part of orange peel extract, 0.2 part of yeast extract, 0.05 part of thyme extract, 0.3 part of white willow bark extract, 1.0 part of mullein extract, 0.15 part of lilium maritime nerve activity whitening factor, 0.15 part of scutellaria baicalensis extract, 0.25 part of oxyresveratrol, 0.4 part of lactobacillus fermentation lysate, 0.7 part of tranexamic acid, 0.9 part of VC ethyl ether, 0.15 part of water-soluble fullerene, 0.7 part of 4-butylresorcinol and 0.03 part of ectoin. The preparation method is the same as example 1.
Example 3
The whitening and spot-fading composition comprises the following raw materials in parts by weight: 2.5 parts of egg oil, 5.5 parts of shea butter, 0.2 part of pterostilbene, 1.1 parts of vitamin E, 1.4 parts of hydrolyzed ceramide III, 0.5 part of orange peel extract, 0.12 part of yeast extract, 0.18 part of thyme serpyllum extract, 0.15 part of white willow bark extract and 0.85 part of mullein extract: 0.012 part of lilium maritimum nerve activity whitening factor, 0.22 part of scutellaria baicalensis extract, 0.2 part of oxyresveratrol, 0.35 part of lactobacillus fermentation lysate, 0.85 part of tranexamic acid, 0.75 part of VC ethyl ether, 0.1 part of water-soluble fullerene, 0.85 part of 4-butyl resorcinol and 0.025 part of ectoin. The preparation method is the same as example 1.
Example 4
The whitening and spot-fading composition comprises the following raw materials in parts by weight: 2 parts of egg yolk oil, 4.2 parts of shea butter, 0.28 part of pterostilbene, 0.9 part of vitamin E, 0.6 part of hydrolyzed ceramide III, 0.55 part of orange peel extract, 0.18 part of yeast extract, 0.08 part of thyme extract, 0.25 part of white willow bark extract, 0.95 part of mullein extract, 0.1 part of lilium maritima nerve activity whitening factor, 0.2 part of scutellaria baicalensis extract, 0.24 part of oxyresveratrol, 0.25 part of lactobacillus fermentation lysate, 0.75 part of tranexamic acid, 0.85 part of VC ethyl ether, 0.12 part of water-soluble fullerene, 0.75 part of 4-butylresorcinol and 0.02 part of ectoin. The preparation method is the same as example 1.
Example 5
The whitening and spot-fading composition comprises the following raw materials in parts by weight: 2 parts of egg yolk oil, 5 parts of shea butter, 0.2 part of pterostilbene, 1 parts of vitamin E, 1 part of hydrolyzed ceramide III, 0.5 part of orange peel extract, 0.15 part of yeast extract, 0.1 part of thyme extract, 0.2 part of white willow bark extract, 0.9 part of mullein extract, 0.1 part of lilium maritime nerve activity whitening factor, 0.2 part of scutellaria baicalensis extract, 0.2 part of oxyresveratrol, 0.3 part of lactobacillus fermentation lysate, 0.8 part of tranexamic acid, 0.8 part of VC ethyl ether, 0.1 part of water-soluble fullerene, 0.8 part of 4-butylresorcinol and 0.02 part of ectoin. The preparation method is the same as example 1.
Comparative example 1
This comparative example differs from example 5 in that: the mass ratio of pterostilbene to orange peel extract, oxidized resveratrol and water-soluble fullerene in the whitening and spot-fading composition is 1: 7: 3: 1.6, namely 0.1 part of pterostilbene, 0.7 part of orange peel extract, 0.3 part of oxyresveratrol and 0.16 part of water-soluble fullerene.
Comparative example 2
This comparative example differs from example 5 in that: the mullein extract is absent from the whitening and spot-lightening composition.
Comparative example 3
This comparative example differs from example 5 in that: the mass ratio of egg yolk oil, lilium maritimum nerve activity whitening factor, scutellaria baicalensis extract and ectoin in the whitening and spot-fading composition is 1: 0.18: 0.3: 0.02 part of egg oil, 0.18 part of lilium brownii nerve activity whitening factor, 0.3 part of scutellaria baicalensis extract and 0.02 part of ectoin.
Comparative example 4
This comparative example differs from example 5 in that: the thymus serpyllum extract is absent from the whitening spot-lightening composition.
Experimental example 1
1. Preparation of a sample:
sample solutions (S1, S2, S3, S4, S5, D1, D2, D3, and D4) were prepared by compounding the whitening and spot-lightening compositions described in examples 1 to 5 and comparative examples 1 to 4, respectively, with a base formulation as a carrier.
In the sample liquid, the whitening and spot-lightening composition accounts for 10% by mass; the basic formula is as follows: 4% glycerol, 0.3% xanthan gum, 2% trehalose, 1.2% SS, 1.8% SSE-20, 0.5% A165, 0.02% EDTA, 3% isononyl isononanoate, 5% 2EHP, 5% GTCC, 1.8% cetostearyl alcohol, 0.08% Tremella heteropolysaccharide, 0.05% WSR205, 0.15% hyaluronic acid, 5% 1.3-butanediol, 0.5% ZEN, 1% SEPIPLUS400, 0.02% heparin sodium, 0.02% polyglutamic acid, 2% glycerol glucoside, 0.2% Chondrus crispus, 4% 1.3-butanediol, 0.25% acetyl tetrapeptide-2, 0.25% oligopeptide-4, 1% E-1008, 0.01% essence, and the balance water.
The preparation method of the sample solution comprises the steps of mixing the components, and stirring for 30min at 40 ℃.
2. Safety test
The sample liquids corresponding to examples 1 to 5 and comparative examples 1 to 4 were subjected to a safety performance test by the following method:
(1) red blood cell hemolysis experiment;
preparation of erythrocyte suspension: selecting healthy rabbits, taking 9mL of blood from heart, adding 1mL of 2% potassium oxalate solution, centrifuging, discarding supernatant, diluting the precipitate to 20mL with 20mmol/L PBS solution, and storing at 4 ℃ for later use. Select samples were diluted with PBS solution to different concentrations, with 5 concentration gradients set for each sample. Taking 10mL of a diluent of a sample to be tested, adding 200 μ L of the erythrocyte suspension (controlling the final concentration of the sample to be 5, 10, 20, 50 and 100mg/mL respectively), taking distilled water as a total blood-dissolving control, taking a PBS solution as a negative control, gently mixing, incubating for 30min at 37 ℃, centrifuging for 10min at the rotating speed of 2000r/min, taking a supernatant, testing the absorbance (A560) of the supernatant at 560nm by using a spectrophotometer, and calculating the hemolysis rate according to the following formula;
hemolysis rate ═ 100% (experimental group a 560-negative control group a560) ×/(whole hemolysis control group a 560-negative control group a560)
A standard curve of hemolysis rate vs. sample concentration was plotted and the sample concentration at which 50% of the erythrocytes were hemolyzed was calculated (HD 50).
(2) Protein denaturation experiments:
diluting a sample to 10g/L by using a PBS (phosphate buffer solution), taking 10mL of a diluent of a sample to be detected, adding 200 mu L of the erythrocyte suspension, taking distilled water as a blank control, taking 1mg/mL of a Sodium Dodecyl Sulfate (SDS) solution as a positive control, gently mixing, incubating for 30min at 37 ℃, centrifuging for 10min at the rotating speed of 2000r/min, taking a supernatant, respectively testing the absorbances A540 and A575 at 540nm and 575nm by using a spectrophotometer, and calculating the protein Denaturation Index (DI) according to the following formula;
DI＝(R1-R2)×100％/(R1-R3)
wherein, R1 is blank control group A575/blank control group A540, R2 is experiment group A575/experiment group A540, R3 is positive control group A575/positive control group A540.
And evaluating the irritation of the sample to be tested according to the L/D value, wherein the L/D value is HD50/DI, and the irritation grading standard of the erythrocyte hemolysis experiment is as follows:
when the L/D is more than 100, the classification is nonirritating; when L/D is more than 10 and less than or equal to 100, the micro-irritation is graded; when L/D is more than 1 and less than or equal to 10, grading the stimulation to be mild stimulation; when L/D is more than 0.1 and less than or equal to 1, grading to be moderate irritation;
the results of the above-described erythrocyte hemolysis experiment and protein denaturation experiment are shown in Table 2 below.
TABLE 2
| Test sample | HD50(mg/L) | DI(％) | L/D | Evaluation of |
| Sample liquid S1 | 26186 | 0.67 | ＞100 | Has no irritation |
| Sample liquid S2 | 25069 | 0.66 | ＞100 | Has no irritation |
| Sample liquid S3 | 26147 | 0.63 | ＞100 | Has no irritation |
| Sample liquid S4 | 26837 | 0.65 | ＞100 | Has no irritation |
| Sample liquid S5 | 26910 | 0.62 | ＞100 | Has no irritation |
| Sample liquid D1 | 26478 | 0.64 | ＞100 | Has no irritation |
| Sample liquid D2 | 24597 | 0.66 | ＞100 | Has no irritation |
| Sample liquid D3 | 26476 | 0.65 | ＞100 | Has no irritation |
| Sample liquid D4 | 25788 | 0.69 | ＞100 | Has no irritation |
According to the safety performance test results, the whitening and spot-lightening composition is mild and has no stimulation; the sample concentration HD50 of the sample solution prepared by the invention when 50% of red blood cells are hemolyzed is more than 20000mg/L, and the protein denaturation index DI is less than 0.75%, so that the whitening and spot-lightening composition can obviously reduce toxic and side effects and irritation, and is safer and more reliable.
3. Tyrosinase inhibition assay
Levodopa (1.5 g/L) was prepared using 0.01mol/L, pH ═ 6.8 phosphate buffer as a substrate, 40. mu.l of the substrate was added to a 96-well plate, and 80. mu.l of phosphate buffer and 40. mu.l of the sample solution were added thereto. Then 40. mu.l of 100U/ml tyrosinase phosphate buffer was added, mixed well and reacted in a water bath at 30 ℃ for 30min, and the absorbance at 490nm was measured. Each group is provided with 3 multiple holes, and the tyrosinase inhibition activity is calculated by the following calculation formula (in the formula, C1 is added with enzyme-free sample liquid, C2 is not added with enzyme-free sample liquid, T1 is added with enzyme-free sample liquid, and T2 is not added with enzyme-free sample liquid):
inhibition rate ═ 1- (A)T1-AT2)/(AC1-AC2)]×100％；
The results of the experiment are shown in table 3.
TABLE 3
The above table shows that the whitening and spot-lightening composition can effectively inhibit tyrosinase, and the inhibition rate is 86.4-93.3%. Meanwhile, according to examples 4 and 5, it was found that when the mass ratio of the egg oil, the lilium maritimum nerve activity whitening factor, the scutellaria baicalensis extract and the ectoin in the white spot-fading composition is 2: 0.1: 0.2: 0.02, the tyrosinase inhibitor has a good inhibition effect on tyrosinase.
4. Determination of the non-enzymatic glycation inhibition of proteins
Non-enzymatic sugars for proteinsEstablishment of a chemoinhibition reaction system: bovine serum albumin and glucose were dissolved in 0.1mol/L PBS buffer (pH 7.4) containing 8mmol/L EDTA, 100U/mL penicillin and 100mg/L streptomycin, respectively, under relatively aseptic conditions so that the final concentrations of the bovine serum albumin and glucose solutions in the system were 20g/L and 400mmol/L, respectively, while the following groups were set as controls or drug groups: 1) a complete saccharification reaction system control group only containing bovine serum albumin and glucose without adding a sample solution; 2) a bovine serum albumin control group to which bovine serum albumin was added without adding a sample solution; 3) a control group to which glucose and sample solution were added; 4) a control group to which bovine serum albumin and a sample solution were added; 5) and adding a sample solution, bovine serum albumin and glucose into the drug group. And (3) transferring the prepared reaction system to 37 ℃, incubating for 40d in a constant-temperature drying box in the dark, and measuring the fluorescence intensity F of each group of reaction liquid by using a fluorescence spectrophotometer under the conditions of excitation wavelength of 370nm, emission wavelength of 440nm and slit of 5 nm. Calculating the inhibition rate I of AGEs5：
I5＝1－(Fr－Fp－Fq)/(Fm－Fn)×100％
Wherein Fm is the F value of the control group 1; fn is the F value of the control group 2; fp is the F value of control group 3; fq is the F value of control 4; fr is the F value of drug group 5.
The results of the experiment are shown in table 4.
TABLE 4
| I5％ | |
| Sample liquid S1 | 86.45 |
| Sample liquid S2 | 84.81 |
| Sample liquid S3 | 89.72 |
| Sample liquid S4 | 85.18 |
| Sample liquid S5 | 96.73 |
| Sample liquid D1 | 68.42 |
| Sample liquid D2 | 78.90 |
| Sample liquid D3 | 82.78 |
| Sample liquid D4 | 84.42 |
| Basic formula sample liquid (without whitening spot-lightening composition) | 9.89 |
The table shows that the whitening and spot-lightening composition has a good inhibition effect on AGEs, and the inhibition rate I5 on non-enzymatic glycosylation is as high as more than 80%. And it is found from examples 3 and 5 that when the mass ratio of pterostilbene, orange peel extract, oxyresveratrol and water-soluble fullerene in the whitening and spot-lightening composition is 2: 5: 2: 1, has better anti-saccharification effect.
In conclusion, according to the whitening and spot-fading composition disclosed by the invention, nineteen active components such as egg yolk oil, shea butter, pterostilbene, vitamin E, hydrolyzed ceramide III, orange peel extract, yeast extract, thyme extract, white willow bark extract, mullein extract, lilium maritimum nerve activity whitening factors, scutellaria baicalensis extract, oxyresveratrol, lactobacillus fermentation lysate, tranexamic acid, VC ethyl ether, water-soluble fullerene, 4-butylresorcinol and ectoin are selected, so that the whitening and spot-fading composition is good in safety and free of toxic and side effects, and the whitening and spot-fading effects are remarkable by means of inhibiting two ways of saccharifying and tyrosinase activity and inhibiting the generation of melanin by composing the whitening and spot-fading active components.
Meanwhile, experiments show that the composition has a remarkable inhibiting effect on tyrosinase and saccharification, wherein the inhibiting rate of the tyrosinase activity is 86.4-93.3%, and the highest inhibiting rate on advanced glycation end products (AGEs) reaches 96.73%.
In addition, the invention also provides application of the whitening and spot-lightening composition in cosmetics.
Specifically, the invention also provides a whitening and spot-lightening cosmetic, which comprises the whitening and spot-lightening composition and acceptable auxiliary materials in the cosmetic.
Wherein the addition amount of the whitening and spot-lightening composition is 10-16% by mass fraction.
The whitening and spot-lightening cosmetic comprises but is not limited to cream, sun cream, facial cleanser, emulsion, toner, facial mask or essence.
The invention provides a whitening spot-lightening cream which comprises the following components in parts by weight: the whitening and spot-lightening composition comprises 16% of the whitening and spot-lightening composition, 4% of glycerol, 0.3% of xanthan gum, 2% of trehalose, 1.2% of SS, 1.8% of SSE-20, 0.5% of A165, 0.02% of EDTA, 3% of isononyl isononanoate, 5% of 2EHP, 5% of GTCC, 1.8% of cetostearyl alcohol, 0.08% of tremella heteropolysaccharide, 0.05% of WSR205, 0.15% of hyaluronic acid, 5% of 1.3-butanediol, 0.5% of ZEN, 1% of SEPIPLUS400, 0.02% of heparin sodium, 0.02% of polyglutamic acid, 2% of glycerol glucoside, 0.2% of crinkle carrageenan, 4% of 1.3-butanediol, 0.25% of acetyl tetrapeptide-2, 0.25% of oligopeptide-4, 1% of E-1008, 0.01% of essence and the balance of water.
The invention also provides a whitening spot-lightening cream which comprises the following components: the whitening and spot-lightening composition comprises 11% of the whitening and spot-lightening composition, 4% of glycerol, 0.3% of xanthan gum, 2% of trehalose, 1.2% of SS, 1.8% of SSE-20, 0.5% of A165, 0.02% of EDTA, 3% of isononyl isononanoate, 5% of 2EHP, 5% of GTCC, 1.8% of cetostearyl alcohol, 0.08% of tremella heteropolysaccharide, 0.05% of WSR205, 0.15% of hyaluronic acid, 5% of 1.3-butanediol, 0.5% of ZEN, 1% of SEPIPLUS400, 0.02% of heparin sodium, 0.02% of polyglutamic acid, 2% of glycerol glucoside, 0.2% of crinkle carrageenan, 4% of 1.3-butanediol, 0.25% of acetyl tetrapeptide-2, 0.25% of oligopeptide-4, 1% of E-1008, 0.01% of essence and the balance of water.
The preparation method of the whitening and spot-fading product is not limited, and the conventional preparation method is adopted.
The above detailed description is specific to one possible embodiment of the present invention, and the embodiment is not intended to limit the scope of the present invention, and all equivalent implementations or modifications without departing from the scope of the present invention should be included in the technical scope of the present invention.
Claims (10)
1. The whitening and spot-lightening composition is characterized by comprising the following raw materials: egg yolk oil, shea butter, pterostilbene, vitamin E, hydrolyzed ceramide III, orange peel extract, yeast extract, thyme extract, white willow bark extract, mullein extract, lilium maritimum nerve activity whitening factor, scutellaria baicalensis extract, oxyresveratrol, lactobacillus fermentation lysate, tranexamic acid, VC ethyl ether, water-soluble fullerene, 4-butylresorcinol, and ectoin.
2. The whitening and spot-lightening composition of claim 1, which is prepared from the following raw materials in parts by weight: 1-3 parts of egg oil, 4-6 parts of shea butter, 0.1-0.3 part of pterostilbene, 0.8-1.2 parts of vitamin E, 0.5-1.5 parts of hydrolyzed ceramide III, 0.4-0.6 part of orange peel extract, 0.1-0.2 part of yeast extract, 0.05-0.15 part of thyme extract, 0.1-0.3 part of white willow bark extract, 0.8-1.0 part of mullein extract, 0.05-0.15 part of lilium maritimum nerve activity whitening factor, 0.15-0.25 part of scutellaria baicalensis extract, 0.15-0.25 part of oxidized resveratrol lysate, 0.2-0.4 part of lactobacillus fermentation product, 0.7-0.9 part of tranexamic acid, 0.7-0.9 part of VC ethyl ether, 0.05-0.15 part of water-soluble fullerene, 0.7-0.9 part of 4-butyl resorcinol and 0.01-0.03-0.01 g of hydantoin.
3. The whitening spot-lightening composition of claim 1, wherein the weight ratio of pterostilbene to orange peel extract to oxyresveratrol to water-soluble fullerene is 2: 5: 2: 1.
4. the whitening spot-lightening composition according to claim 1, wherein the mass ratio of the egg yolk oil, the lilium maritimum nerve activity whitening factor, the scutellaria baicalensis extract and the ectoin is 2: 0.1: 0.2: 0.02.
5. the whitening and spot-lightening composition of claim 1, which is prepared from the following raw materials in parts by weight: 2 parts of egg yolk oil, 5 parts of shea butter, 0.2 part of pterostilbene, 1 parts of vitamin E, 1 part of hydrolyzed ceramide III, 0.5 part of orange peel extract, 0.15 part of yeast extract, 0.1 part of thyme extract, 0.2 part of white willow bark extract, 0.9 part of mullein extract, 0.1 part of lilium maritime nerve activity whitening factor, 0.2 part of scutellaria baicalensis extract, 0.2 part of oxyresveratrol, 0.3 part of lactobacillus fermentation lysate, 0.8 part of tranexamic acid, 0.8 part of VC ethyl ether, 0.1 part of water-soluble fullerene, 0.8 part of 4-butylresorcinol and 0.02 part of ectoin.
6. Use of the whitening and spot-lightening composition according to any one of claims 1 to 5 in cosmetics.
7. A whitening and spot-lightening cosmetic characterized by comprising the whitening and spot-lightening composition as claimed in any one of claims 1 to 5 and cosmetically acceptable auxiliary materials.
8. The whitening and spot-lightening cosmetic as claimed in claim 7, wherein the whitening and spot-lightening cosmetic comprises a cream, a sun block, a sunscreen cream, a face cleanser, an emulsion, a toner, a mask or a essence.
9. The whitening spot-lightening cosmetic according to claim 7, wherein the whitening spot-lightening composition is added in an amount of 10 to 16% by mass.
10. The whitening and spot-lightening cosmetic according to claim 7, wherein the whitening and spot-lightening cosmetic comprises, in mass fraction: 10-16% of the whitening and spot-lightening composition, 4% of glycerin, 0.3% of xanthan gum, 2% of trehalose, 1.2% of SS, 1.8% of SSE-20, 0.5% of A165, 0.02% of EDTA, 3% of isononyl isononanoate, 5% of 2EHP, 5% of GTCC, 1.8% of cetostearyl alcohol, 0.08% of tremella heteropolysaccharide, 0.05% of WSR205, 0.15% of hyaluronic acid, 5% of 1.3-butanediol, 0.5% of ZEN, 1% of SEPIPLUS400, 0.02% of heparin sodium, 0.02% of polyglutamic acid, 2% of glycerol glucoside, 0.2% of crinkle carrageenan, 4% of 1.3-butanediol, 0.25% of acetyl tetrapeptide-2, 0.25% of oligopeptide-4, 1% of E-1008, 0.01% of essence and the balance of water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010656244.0A CN111743851B (en) | 2020-07-09 | 2020-07-09 | Whitening and spot-fading composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010656244.0A CN111743851B (en) | 2020-07-09 | 2020-07-09 | Whitening and spot-fading composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111743851A true CN111743851A (en) | 2020-10-09 |
| CN111743851B CN111743851B (en) | 2021-01-12 |
Family
ID=72710943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010656244.0A Active CN111743851B (en) | 2020-07-09 | 2020-07-09 | Whitening and spot-fading composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111743851B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113730322A (en) * | 2021-10-22 | 2021-12-03 | 广州市胜梅化妆品有限公司 | Anti-allergy soothing cosmetic |
| CN114042001A (en) * | 2021-10-18 | 2022-02-15 | 深圳市兰亭科技股份有限公司 | Whitening composition with synergistic effect and application thereof |
| CN114272147A (en) * | 2021-09-30 | 2022-04-05 | 广州杰铿生物科技有限公司 | Whitening composition and preparation method thereof |
| CN114681358A (en) * | 2022-02-16 | 2022-07-01 | 合肥卡迪尔生物科技有限公司 | Tyrosinase activity inhibitor and skin care product with synergistic whitening effect |
| CN115944577A (en) * | 2022-12-29 | 2023-04-11 | 羽楠(广州)化妆品有限公司 | Whitening composition and application thereof, whitening cosmetic and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110012601A (en) * | 2009-07-31 | 2011-02-09 | 권세환 | Cosmetic compositions, soaf for body, soaf for scalp and shampoo for scalp using an extract of a sweetflag |
| CN106139077A (en) * | 2016-07-14 | 2016-11-23 | 深圳波顿香料有限公司 | A kind of fragrant plant hair growth promoter and preparation method thereof |
| CN106176566A (en) * | 2016-08-23 | 2016-12-07 | 上海新高姿化妆品有限公司 | Cosmetic composition with white-skinned face function and preparation method thereof |
| CN106580797A (en) * | 2016-12-30 | 2017-04-26 | 广州科盈化妆品有限公司 | Whitening and freckle-removing cream and preparation method thereof |
| CN111249215A (en) * | 2020-02-28 | 2020-06-09 | 广东肽世家生物科技有限公司 | Multi-effect whitening and freckle-removing cream and preparation method thereof |
-
2020
- 2020-07-09 CN CN202010656244.0A patent/CN111743851B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110012601A (en) * | 2009-07-31 | 2011-02-09 | 권세환 | Cosmetic compositions, soaf for body, soaf for scalp and shampoo for scalp using an extract of a sweetflag |
| CN106139077A (en) * | 2016-07-14 | 2016-11-23 | 深圳波顿香料有限公司 | A kind of fragrant plant hair growth promoter and preparation method thereof |
| CN106176566A (en) * | 2016-08-23 | 2016-12-07 | 上海新高姿化妆品有限公司 | Cosmetic composition with white-skinned face function and preparation method thereof |
| CN106580797A (en) * | 2016-12-30 | 2017-04-26 | 广州科盈化妆品有限公司 | Whitening and freckle-removing cream and preparation method thereof |
| CN111249215A (en) * | 2020-02-28 | 2020-06-09 | 广东肽世家生物科技有限公司 | Multi-effect whitening and freckle-removing cream and preparation method thereof |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114272147A (en) * | 2021-09-30 | 2022-04-05 | 广州杰铿生物科技有限公司 | Whitening composition and preparation method thereof |
| CN114272147B (en) * | 2021-09-30 | 2023-11-03 | 广州杰铿生物科技有限公司 | Whitening composition and preparation method thereof |
| CN114042001A (en) * | 2021-10-18 | 2022-02-15 | 深圳市兰亭科技股份有限公司 | Whitening composition with synergistic effect and application thereof |
| CN113730322A (en) * | 2021-10-22 | 2021-12-03 | 广州市胜梅化妆品有限公司 | Anti-allergy soothing cosmetic |
| CN113730322B (en) * | 2021-10-22 | 2023-01-03 | 广州市胜梅化妆品有限公司 | Soothing cosmetic |
| CN114681358A (en) * | 2022-02-16 | 2022-07-01 | 合肥卡迪尔生物科技有限公司 | Tyrosinase activity inhibitor and skin care product with synergistic whitening effect |
| CN114681358B (en) * | 2022-02-16 | 2023-11-21 | 合肥卡迪尔生物科技有限公司 | Tyrosinase activity inhibitor and skin care product with synergistic whitening effect |
| CN115944577A (en) * | 2022-12-29 | 2023-04-11 | 羽楠(广州)化妆品有限公司 | Whitening composition and application thereof, whitening cosmetic and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111743851B (en) | 2021-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111743851B (en) | Whitening and spot-fading composition and application thereof | |
| CN112494406A (en) | Whitening and freckle-removing cosmetic and preparation method thereof | |
| CN109453087B (en) | Whitening skin-penetrating lotion, preparation method thereof and whitening cosmetic additive | |
| CN111603434B (en) | Composition for improving skin wrinkles and cosmetic thereof | |
| CN111067835A (en) | Whitening composition for resisting skin saccharification reaction and preparation method thereof | |
| CN113520942B (en) | Anti-oxidation and anti-aging five-ginseng fermentation product and preparation method and application thereof | |
| CN109330954B (en) | Whitening skin brightening lotion, preparation method thereof and tyrosinase inhibitor | |
| CN107375043A (en) | A kind of application of composition containing small-micelle water and said composition in cosmetics | |
| CN112603870A (en) | Multi-effect essence cream and preparation method thereof | |
| CN104306323A (en) | Cordyceps-militaris-ingredient contained eye cream and preparing method of cordyceps-militaris-ingredient contained eye cream | |
| TWI784229B (en) | Lonicera japonica thunb ferment, preparation method thereof and use thereof for improving skin appearance and anti-aging | |
| CN110742843B (en) | Anti-aging traditional Chinese medicine extract of ginseng and glossy ganoderma as well as preparation method and application thereof | |
| CN111603404B (en) | Skin care essence containing cell extracting solution and preparation method thereof | |
| CN104434760A (en) | Facial cream containing ingredient of cordyceps militaris and preparation method thereof | |
| CN116421525B (en) | Paeonia root extract and preparation method thereof | |
| CN113116798A (en) | Face cream containing anti-aging composition and preparation method thereof | |
| CN111658587A (en) | Collagenase inhibitor composition, anti-aging water lotion and preparation method thereof | |
| CN115414289A (en) | Cordyceps flower cosmetics and preparation method thereof | |
| CN105832648A (en) | Skin-nourishing anti-aging peony seed oil face mask and manufacturing method thereof | |
| CN104352426A (en) | Facial mask fluid containing cordyceps militaris ingredient and preparation method thereof | |
| CN113318024A (en) | Saussurea involucrate and lucid ganoderma essence skin-tendering cream and preparation method thereof | |
| CN109568234B (en) | Gel type safflower whitening mask and preparation method thereof | |
| CN103340808A (en) | Preparation technology for pseudo-ginseng medicament night cream | |
| CN112933028A (en) | Skin lotion containing anti-aging composition and preparation method thereof | |
| CN114931537B (en) | Composite ferment capable of delaying aging and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |